Two days ago, PTC Therapeutics announced that the drug candidate PTC518 has entered into a “Phase 1 Clinical Trial”. The initial results are expected in the first half of 2021. PTC518 is an orally bioavailable molecule. In other words, the drug candidate is administered in the form of a pill taken through the mouth. In…
Read more
The HD Insights Podcast by the Huntington Study Group is an interview series with the people working in Huntington’s disease research and treatments. The Huntington Study Group is a non-profit research organisation formed in 1993 – the same year as the Huntington’s disease (HD) gene was discovered. Learn more: The Insight Podcast The group is dedicated…
Read more
Join webinars, get updated on the latest research and learn more about our new project Moving Forward! Read our Autumn Newsletter! Click here.
DOMINO-HD is a European study funded by the EU Joint Programme for Neurodegenerative Disease. The aim of the study is to investigate the relationship between genetic and lifestyle factors and Huntington’s disease symptom progression. Written by Dr. Cheney Drew Research has shown that the rate of decline in people with Huntington’s disease (HD) can be…
Read more
We are launching “Moving Forward”. The new project aims at including people from Huntington’s disease families in drug development by facilitating an active and long-lasting commitment from patients and family members. Written by Filipa Júlio, Project Manager in Moving Forward Between September 2016 and December 2019, the European Huntington Association (EHA) has run multiple European and…
Read more
The Swiss pharmaceutical company Novartis is currently developing a pill for Huntington’s disease. Two days ago, the US Food and Drug Administration, FDA, granted an Orphan Drug Designation for the drug. The drug is called branaplam (LMI070) and is administered in the form of a pill that you take through your mouth. At the moment,…
Read more
In June, two people enrolled in the first gene therapy trial for Huntington’s disease. Now, two more participants have joined the study uniQure states in a new press release. UniQure is currently developing a gene therapy for Huntington’s disease. The drug candidate is called AMT-130 and is a gene therapy. In other words, it seeks to…
Read more
At the moment, there is a lot of research being done in the Huntington’s disease field. As Sarah Tabrizi from University College London stated during the meeting: – It’s a really rich time for us to be involved in Huntington’s disease. Get an update on some of the trials and studies here! Find all the…
Read more
Due to instability in the gene, Huntington’s disease symptoms may begin earlier in life. By targeting proteins involved in DNA damage repair, we might be able to reduce the levels of instability and delay disease progression. Many repair proteins work to maintain the machinery that copies DNA. One of these proteins – so-called Huntington’s disease…
Read more
The European Huntington’s Disease Network (EHDN) Newsletter appears three times a year. This year’s second edition is dedicated to the impact of Covid-19: the problems it has created but also the adaptability and the positive trends. In the newsletter, you can learn more about telemedicine. Here, Alzbeta Mühlbäck, our own doctor, states: – Though we…
Read more
